Cleaning compositions for solid surfaces – auxiliary compositions – Cleaning compositions or processes of preparing – For cleaning a specific substrate or removing a specific...
Reexamination Certificate
2001-03-08
2003-07-08
Boyer, Charles (Department: 1751)
Cleaning compositions for solid surfaces, auxiliary compositions
Cleaning compositions or processes of preparing
For cleaning a specific substrate or removing a specific...
C510S135000, C510S136000, C510S155000, C510S421000, C510S432000, C510S437000, C510S491000
Reexamination Certificate
active
06589922
ABSTRACT:
FIELD OF THE INVENTION
The invention pertains to the field of cleansers for skin, and most particularly to skin cleansers that may be used on sensitive, damaged, diseased, or irritated skin.
BACKGROUND OF THE INVENTION
Cleansing products represent one of the major risk factors for occupational dermatitis, particularly hand dermatitis. Chronic irritant contact dermatitis is due in many cases to repeated exposure to weak irritants, such as present in many skin cleansers. Also, certain endogenous skin diseases, such as atopic dermatitis, are exacerbated by exposure to irritants found in these cleansing products. Additionally, many individuals who have sensitive skin, even without having dermatitis, experience symptoms of irritation, such as redness, stinging, tingling, burning and itching, when using topical cleansing products on intact skin.
The mildness (lack of tendency to cause irritation) of a cleansing product is related to the formulation of the particular detergent or detergents and their concentration in the cleansing product. Also, the risk of chronic irritant dermatitis or exacerbation of endogenous dermatitis increases with increased frequency of washing. This is especially a problem in occupations that require frequent hand washing, such as in workers in the medical and food service fields.
CETAPHIL® Cleanser (Galderma Laboratories, Ft. Worth, Tex.) is recognized as the leading mild skin cleanser and is frequently recommended by physicians for use by patients with atopic dermatitis and hand dermatitis. Even though this product is recognized as being mild, tests have shown that its use results in significant irritation to human skin when evaluated in a patch test. Chronic use of CETAPHIL® or other cleansing products made for skin can perpetuate or worsen a dermatitis, particularly in individuals with sensitive skin.
Therefore, a significant need exists for a milder skin cleanser for individuals with sensitive skin, atopic dermatitis, or latent, incipient or frank hand dermatitis. In addition to being mild, such a hand cleanser should be effective as a cleanser and should moisturize.
SUMMARY OF THE INVENTION
The present invention is a major improvement in mild skin cleansers and in methods of cleansing skin. Although useful in individuals with normal skin, the invention is most useful in those individuals with sensitive skin who are vulnerable to developing skin disorders and those individuals who are currently suffering from such disorders.
In one embodiment, the invention is a composition for cleansing skin, especially for diseased or sensitive skin. The composition is most useful for cleaning the hands, but may also be used to clean the skin on any other part of the body. The composition of the invention is demonstrably less irritating than CETAPHIL® Cleanser in a comparative repeat insult patch test. The composition is stable, cosmetically elegant, well tolerated by users, and cleanses effectively while moisturizing the skin. Compositions of this invention may be safely used for frequent cleansings such as hand washings required of food workers and medical personnel. The composition may also be used to prevent or to treat or manage dermatitis, especially hand dermatitis.
In another embodiment, the invention is a method for cleaning skin, such as the skin of the hands. According to this embodiment, a formulation containing the composition of the invention is applied to the skin. The formulation is then removed from the skin, either with or without water.
In another embodiment, the invention is a method for prevention of dermatitis in individuals susceptible to developing dermatitis, especially of the hands. According to this embodiment, the invention comprises cleansing the skin with a formulation containing the composition of the invention by applying the formulation to the skin and then removing it from the skin.
In another embodiment, the invention is a method for treatment or management of dermatitis, especially hand dermatitis. According to this embodiment, an individual suffering from this condition cleanses his or her skin with a formulation containing the composition of the invention.
In another embodiment, the invention is a method for making a moisturizing skin cleanser. According to this embodiment, the method includes combining one or more non-ionic surfactants with a glyceryl monoester. Preferably, one or more saturated fatty alcohols is also combined with the surfactant and the glyceryl monoester.
DETAILED DESCRIPTION OF THE INVENTION
The composition of the invention is useful as a component of a formulation, or as the entire formulation, that is useful as a skin cleanser, particularly for the hands. The skin cleanser is especially useful for preventing dermatitis in susceptible individuals and in managing and treating individuals suffering from dermatitis, such as atopic dermatitis or hand dermatitis. The cleanser of the invention may be used with or without water during the cleansing process. The water may be used to increase the lather of the cleanser or to rinse the cleanser from the skin of the user. Cleansing without water may be accomplished by massaging the cleanser onto the skin to be cleaned and then wiping any soil and excess cleanser off the skin with a cloth or paper towel or facial tissue.
According to the invention, the composition of the invention contains one or more non-ionic surfactants. Examples of suitable non-ionic surfactants include poloxamers and steareths.
Poloxamers are also known as polyoxyethylene polyoxypropylene block polymers. They are sold under the trade name PLURONIC™ by BASF of Washington, N.J., which markets several grades of PLURONIC™. A preferred poloxamer for the composition of the invention is poloxamer 123, as described in the National Formulary. The BASF name for this poloxamer is PLURONIC L43.
One company that makes steareths is ICI America of Wilmington, Del., where they are sold under the trade name BRIJ™. One preferred steareth for the composition of the invention is BRIJ 72, which is also known as steareth-2. Other names for steareth-2 are PEG-2 Stearyl Ether, Polyoxyethylene (2) Stearyl Ether, and Polyethylene Glycol 100 Stearyl Ether. Other preferred steareths for the composition of the invention are BRIJ 78 and 721, which are also known as steareth-20 and 21, respectively.
Suitable total concentrations of non-ionic surfactant for the composition and formulation of the invention are from about 0.5% to about 10% by weight for poloxamers and/or steareths. A preferred range is from about 1% to about 5%, and a most preferred range from about 1.25% to about 2.5%.
The composition of the invention further contains one or more glyceryl monoesters of a fatty acid, also known as fatty acid monoglycerides. The terms “glyceryl monoester” and “monoglyceride” are used synonymously throughout this specification to in reference to fatty acid esters. It has been discovered that such glyceryl monoesters in accordance with the invention provide unexpected benefits to the compositions of the invention, including physical stabilization and reproducibility of pharmaceutical attributes. The glyceryl monoesters have also unexpectedly been found to contribute to the moisturizing properties and to the mildness of the compositions of the invention. Preferably, the monoester content or purity, also known as the monoglyceride content or purity, of the glyceryl monoester is at least about 50%, although it may be lower if desired, such as between 35% and 50%. Preferably, the fatty acid component of the glyceryl monoester is of fatty acids having a chain length of between C8 to C22, which fatty acids are preferably substantially or entirely saturated.
Suitable total concentrations of glyceryl monoester for the composition and formulation of the invention are from about 0.1% to about 5% by weight. A preferred concentration of glyceryl monoester is from about 0.5% to 2%. The most preferred concentration is about 1%.
A preferred glyceryl monoester is glyceryl monolaurate, sold for example under the trade name IMWITOR 312 (Salol Co., Hou
Bean Kevin
Dow Gordon J.
Boyer Charles
Dow Pharmaceutical Sciences
Eisenberg, Esq. Howard
LandOfFree
Skin cleanser comprising a steareth, poloxamer, and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Skin cleanser comprising a steareth, poloxamer, and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Skin cleanser comprising a steareth, poloxamer, and a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3048076